Sandoz reported a 9% growth in net sales of generics and biosimilars to third parties for 2024, marking a strong first ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesMEDIA RELEASEFY 2024 net sales[1] of USD 10.4 billion, up by 9%[2] in ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Sandoz is one of the largest biosimilars players in the world and we believe it is well-positioned to benefit from the fast pace of growth the market is expected to enjoy over the next decade. Sandoz ...

In April, Sandoz leveraged a private-label agreement in the US to accelerate patient switching to its biosimilar; Hyrimoz® (adalimumab) is now the leading adalimumab biosimilar in the US market.

The commercial availability of Pyzchiva®, which builds on the US launch of Hyrimoz® in July 2023, marks an important step in the Sandoz strategic ambition to become number one in biosimilars in ...